These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009 [TBL] [Abstract][Full Text] [Related]
10. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Noone PG; Hamblett N; Accurso F; Aitken ML; Boyle M; Dovey M; Gibson R; Johnson C; Kellerman D; Konstan MW; Milgram L; Mundahl J; Retsch-Bogort G; Rodman D; Williams-Warren J; Wilmott RW; Zeitlin P; Ramsey B; Pediatr Pulmonol; 2001 Aug; 32(2):122-8. PubMed ID: 11477729 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS; Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352 [TBL] [Abstract][Full Text] [Related]
12. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Tirouvanziam R; Conrad CK; Bottiglieri T; Herzenberg LA; Moss RB; Herzenberg LA Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4628-33. PubMed ID: 16537378 [TBL] [Abstract][Full Text] [Related]
13. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Ordoñez CL; Stulbarg M; Grundland H; Liu JT; Boushey HA Pediatr Pulmonol; 2001 Jul; 32(1):29-37. PubMed ID: 11416873 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Hu J; Zhang Q; Ren X; Sun Z; Quan Q Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):594-9. PubMed ID: 25732608 [TBL] [Abstract][Full Text] [Related]
15. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study. Skov M; Pressler T; Lykkesfeldt J; Poulsen HE; Jensen PØ; Johansen HK; Qvist T; Kræmer D; Høiby N; Ciofu O J Cyst Fibros; 2015 Mar; 14(2):211-8. PubMed ID: 25458464 [TBL] [Abstract][Full Text] [Related]
16. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Correa MJ; Mariz HA; Andrade LE; Kayser C Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027 [TBL] [Abstract][Full Text] [Related]
17. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138 [TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395 [TBL] [Abstract][Full Text] [Related]
19. N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Treweeke AT; Winterburn TJ; Mackenzie I; Barrett F; Barr C; Rushworth GF; Dransfield I; MacRury SM; Megson IL Diabetologia; 2012 Nov; 55(11):2920-8. PubMed ID: 22935960 [TBL] [Abstract][Full Text] [Related]
20. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]